Starton Therapeutics is disrupting healthcare to positively impact the lives of people with cancer by developing therapies that build upon current treatments safely and effectively. Its proprietary transdermal technology increases the efficacy of approved drugs to make them more tolerable and expand their potential use thereby extending and improving the quality of life of people with cancer.
Starton Therapeutics’ business model is faster to market and less capital intensive than new drug development and the company is seeking capital to advance its clinical studies. It is inviting investors to join its mission of transforming standard of care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer.
Watch Unicorn Hunters on demand and if you are intestered in investing, click here.
Before you consider S1, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and S1 wasn't on the list.
While S1 currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
